Aacr 2020 meeting
Investor Relations | CytomX Therapeutics, Inc.
(AACR) 2020 Virtual Annual Meeting II. These data support the strategy of expanding the therapeutic index for CTLA-4 therapy using CytomX’s Probody technology and provides rationale for the ongoing clinical studies of these agents. CX-072: Anti-PD-L1 Probody Immunotherapeutic.
Investor Relations | ORIC Pharmaceuticals, Inc.
2020 American Association for Cancer Research (AACR) Annual Virtual Meeting II. Key findings of the presentations included: A transcriptional signature of glucocorticoid receptor (GR) activity was identified in a panel of 32 cell lines across triple negative breast cancer, non-small cell lung.
Investor Relations | VBL Therapeutics
In June 2020, at the 2020 American Association of Cancer Research (AACR) virtual annual meeting, we presented data showing that our proprietary MOSPD2 bi-specific full-IgG antibody candidates mediated killing of tumor cells by CD8 T-cells in a dose-dependent manner, induced T-cell activation in-vivo and extended survival of animals carrying ...
iTeos Therapeutics | Investors
AACR preclinical data presentation demonstrating an encouraging preclinical therapeutic index: In June 2020, the. company presented data for EOS-448 showing potent antitumor activity and a favorable tolerability profile in preclinical studies at the American Association of Cancer Research II Virtual Annual Meeting. Corporate Updates
Press Releases | Verastem Inc.
Presented New Preclinical VS-6766/Defactinib Combination Data in Uveal Melanoma at AACR 2020 Virtual Meeting II. In this study, researchers. identified and reinforced that FAK inhibition is a viable pathway to inhibit downstream from the GNAQ pathway, which is constitutively active in uveal melanoma.
Investors | Syndax Pharmaceuticals, Inc.
The presentation, which was featured at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting I, also highlighted preclinical findings, including data recently published in Cancer Cell and Science magazine, supporting the potential of single-agent menin-MLL inhibition to serve as an effective intervention for both MLL ...
Surface Oncology | Investors and Media
In June, presented updated preclinical data on SRF813 and lead candidates SRF617 and SRF388 at the 2020 AACR virtual annual meeting. Presentations can be found in the Posters & Publications section on this page. Advanced SRF813, a high affinity, fully human IgG1 antibody against CD112R (PVRIG) into IND enabling studies.
Investor Overview | Jounce Therapeutics, Inc.
2020, Jounce presented new translational data on vopratelimab at the AACR Virtual Annual Meeting detailing important characteristics of ICOS hi CD4 T cells associated with vopratelimab treatment that may contribute to durable clinical responses in monotherapy and combination.
Jounce Therapeutics, Inc.
Jounce will present new preclinical data at the second portion of the virtual 2020 American Association for Cancer Research (AACR) annual meeting being held June 22-24 and expects to file an Investigational New Drug (IND) application in the first half of 2021.
Sutro Biopharma, Inc.
“We were looking forward to sharing updated safety and efficacy data from our Phase 1 trial for STRO-002 during the AACR Annual Meeting 2020 as a follow up to the encouraging interim safety data we presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in late October 2019,” said Bill Newell, Sutro’s Chief Executive Officer.
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.